natgillin/translations-raw huggingface dataset:
Zonisamidbehandling er forbundet med hyperkloræmisk, non-aniongap, metabolisk acidose (dvs. nedsat hydrogencarbonat under det normale referenceinterval i fravær af kronisk respiratorisk alkalose). 
Hyperchloraemic, non-anion gap, metabolic acidosis (i.e. decreased serum bicarbonate below the normal reference range in the absence of chronic respiratory alkalosis) is associated with zonisamide treatment.
4.8), men i betragtning af hvor alvorligt vægttab kan være hos børn, bør vægten monitoreres hos denne population. 
The incidence of decreased body weight is consistent across age groups (see section 4.8); however, given the potential seriousness of weight loss in children, weight should be monitored in this population.
A FREMSTILLER ANSVARLIG FOR BATCHFRIGIVELSE 
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Zonisamide Mylan 100 mg fås i blisterpakninger med 28, 56, 98 eller 196 kapsler, og i perforerede blisterpakninger, der indeholder 56 × 1 kapsler. 
Zonisamide Mylan 100 mg are available in blister packs of 28, 56, 98 and 196 capsules and perforated unit dose blister packs of 56 x 1 capsules.
En meget høj plasmakoncentration på 100,1 µg/ml zonisamid blev registreret ca. 31 timer efter, at en patient tog en overdosis af zonisamid og clonazepam. 
A very high plasma concentration of 100.1 μg/ml zonisamide was recorded approximately 31 hours after a patient took an overdose of zonisamide and clonazepam; the patient became comatose and had respiratory depression, but recovered consciousness five days later and had no sequelae.
Hos børn i alderen 6 - 17 år var bivirkningerne de samme som beskrevet herunder, dog med følgende undtagelser: lungebetændelse, væskemangel (dehydrering), nedsat svedproduktion (almindelig) og unormale prøver for leverfunktion (ikke almindelig), mellemørebetændelse, ondt i halsen, bihule- eller lungebetændelse, hose, næseblod, dryppende næse, mavepine, opkast, kløe, eksem og feber. 
In children ages 6 - 17 years old, side effects were consistent with those described below with the following exceptions: pneumonia, dehydration, sweating decreased (common), abnormal liver enzymes (uncommon), middle ear infection, sore throat, sinus and chest infections, cough, nosebleeds, runny nose, stomach pain, vomiting, rash, eczema and fever.
Nephrolithiasis Sten i urinvejene Hydronephrose Nyresvigt 
Nephrolithiasis Calculus urinary Hydronephrosis Renal failure
Hvis De er kvinde i den fødedygtige alder, skal De anvende passende svangerskabsforebyggelse, mens De tager Zonisamide Mylan og i en måned efter, De er holdt op med Zonisamide Mylan. 
If you are a woman of childbearing age you must use adequate contraception while taking, and for one month after stopping, Zonisamide Mylan.
MonoterapiNydiagnosticerede voksne patienter 
MonotherapyNewly diagnosed adult patients
Koncentrationen i modermælk er den samme som i moderens plasma. 
Zonisamide is excreted in human milk; the concentration in breast milk is similar to maternal plasma.
Nystagmus Talebesvær Tremor Krampeanfald 
Nystagmus Speech disorder Tremor
Dosistitrering og vedligeholdelsesdosis 
Dosage escalation and maintenance
Øvrige indholdsstoffer: - indhold i kapslen: mikrokrystallinsk cellulose, hydrogeneret vegetabilsk olie og natriumlaurilsulfat - indhold kapselskallen: gelatine, titandioxid (E171) - prægeblæk indeholder: shellac, sort jernoxid (E172) og kaliumhydroxid. 
The other ingredients are: - capsule contents: microcrystalline cellulose, hydrogenated vegetable oil and sodium laurilsulfate - capsule shell: gelatin and titanium dioxide (E171) - printing ink: shellac, black iron oxide (E172) and potassium hydroxide.
Tilfælde med nedsat svedproduktion og forhøjet legemstemperatur er blevet rapporteret hovedsagelig hos pædiatriske patienter (se den fuldstændige advarsel i pkt. 
Cases of decreased sweating and elevated body temperature have been reported mainly in paediatric patients (see section 4.4 Paediatric Population for full warning).
Læger skal drøfte, hvor alvorligt hedeslag kan være, i hvilke situationer det kan forekomme, samt hvilke handlinger der skal træffes i tilfælde af tegn eller symptomer, med patienterne og deres omsorgsgivere. 
Physicians should discuss with patients and their carers the potential seriousness of heat stroke, situations in which it might arise, as well as action to take in the event of any signs or symptoms.
Børn og unge (5 - 18 år): Begrænsede data tyder på, at farmakokinetikken hos børn og unge, som doseres til steady state med 1, 7 eller 12 mg/kg dagligt i delte doser, er den samme, som blev observeret hos voksne efter korrektion for legemsvægt. 
Limited data indicate that pharmacokinetics in children and adolescents dosed to steady state at 1, 7 or 12 mg/kg daily, in divided doses, are similar to those observed in adults, after adjustment for bodyweight.
Personer, som fik flere anfald, blev titreret til den maksimale måldosis på 1.200 mg carbamazepin eller 500 mg zonisamid. 
Subjects who experienced a further seizure were titrated to the maximal target dose of 1200 mg carbamazepine or 500 mg zonisamide.
Øges med ugentlige intervaller i trin af 1 mg/kg 
Increase at weekly intervals in increments of 1 mg/kg
Hos patienter med nyreinsufficiens var den renale clearance af enkeltdoser af zonisamid positivt korreleret til creatininclearance. 
In subjects with renal impairment, renal clearance of single doses of zonisamide was positively correlated with creatinine clearance.
Dosisjustering er ikke nødvendig ved administration sammen med andre antiepileptika, herunder CYP3A4-inducere. 
There is no need for dose adjustment with any of the AEDs including CYP3A4 inducers.
PVC/PVDC-aluminiumsfolie-blisterpakning i æsker af karton, der indeholder 28, 56, 98 og 196 kapsler. 
PVC-PVdC/Aluminium foil blisters in cardboard cartons containing 28, 56, 98 and 196 capsules.
Undertype af anfald (6 måneders anfaldsfri PPpopulation) 
Seizure Sub-type (6 month seizure freedom-PP population) All partial
P-glykoprotein-substrat 
P-gp substrate
Uge 3 + 4 Uge 5 til 10 
Week 1 + 2 Week 3 + 4 Week 5 to 10
Når Zonisamide Mylan seponeres, bør det ske gradvist (se pkt. 
When Zonisamide Mylan treatment is to be discontinued, it should be withdrawn gradually (see section 4.4).
Den renale clearance af uomdannet zonisamid er forholdsvis lav (ca. 3,5 ml/min). 
Renal clearance of unchanged zonisamide is relatively low (approximately 3.5 ml/min); about 15 - 30 % of the dose is eliminated unchanged.
Faldet i hydrogencarbonat er sædvanligvis lille til moderat (gennemsnitligt ca. 3,5 mEq/l ved døgndoser på 300 mg hos voksne). 
The amounts by which bicarbonate is decreased are usually small - moderate (average decrease of approximately 3.5 mEq/l at daily doses of 300 mg in adults); rarely patients can experience more severe decreases.
• Barnet skal undgå voldsom fysisk udfoldelse, navnlig i varmt vejr 
• The child must avoid heavy exercise especially when the weather is hot
Ændringer i zonisamidkoncentrationen kan dog forekomme, hvis samtidig behandling med et CYP3A4 inducerende antiepileptikum eller andre lægemidler seponeres, får dosis justeret eller påbegyndes og justering af zonisamid-dosis kan blive nødvendig. 
These effects are unlikely to be of clinical significance when zonisamide is added to existing therapy; however, changes in zonisamide concentrations may occur if concomitant CYP3A4-inducing anti-epileptic or other medicinal products are withdrawn, dose adjusted or introduced, an adjustment of the zonisamide dose may be required.
Uge 3 til 5 
Week 2 Week 3 to 5
Et syndrom, der består af akut myopi og sekundær glaucoma angulo clauso, er rapporteret hos voksne patienter og pædiatriske patienter, som får zonisamid. 
Acute myopia and secondary angle closure glaucoma A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in adult and paediatric patients receiving zonisamide.
Zonisamid bør anvendes med forsigtighed hos voksne patienter, der samtidig behandles med kulsyreanhydrasehæmmere såsom topiramat og acetazolamid, da der foreligger utilstrækkelige data til at udelukke en mulig farmakodynamisk interaktion (se pkt. 
Zonisamide should be used with caution in adult patients treated concomitantly with carbonic anhydrase inhibitors such as topiramate and acetazolamide, as there are insufficient data to rule out a possible pharmacodynamic interaction (see section 4.4).
Zonisamide Mylan 25 mg og 50 mg fås i blisterpakninger med 14, 28 eller 56 kapsler, og i perforerede blisterpakninger, der indeholder 14 × 1 kapsler. 
Zonisamide Mylan 25 mg and 50 mg are available in blister packs of 14, 28, 56 capsules and perforated unit dose blister packs of 14 x 1 capsules.
Bivirkninger forbundet med zonisamid registreret fra kliniske studier og overvågning efter markedsføring er anført i nedenstående tabel. 
Adverse reactions associated with zonisamide obtained from clinical studies and post-marketing surveillance are tabulated below.
Blod og lymfesystem 
Blood and lymphatic disorders
Zonisamid Carbamazepin n (ITT-population) Seks måneder uden anfald 
Efficacy results for Monotherapy Study 310 Zonisamide Carbamazepine n (ITT population) Six months seizure freedom
Zonisamide Mylan indeholder det aktive stof zonisamid og anvendes mod epilepsi (et antiepileptikum). 
What Zonisamide Mylan is and what it is used for Zonisamide Mylan contains the active substance zonisamide, and is used as an antiepileptic medicine.
Kombinationen af zonisamid med andre lægemidler, som kan medføre urolithiasis kan øge risikoen for udvikling af nyresten. 
The combination of zonisamide with other medicinal products that may lead to urolithiasis may enhance the risk of developing kidney stones; therefore the concomitant administration of such medicinal products should be avoided.
Obstipation Diarré Dyspepsi Kvalme Opkastning 
Constipation Diarrhoea Dyspepsia Nausea Vomiting
- uden CYP3A4induktorer 
CYP3A4-inducing agents
- uden CYP3A4induktorer eller ved nedsat nyre- eller leverfunktion 
CYP3A4-inducing agents; or with renal or hepatic impairment
Irritabilitet Konfusionstilstande Depression 
Agitation Irritability Confusional state
Hver hård kapsel er ca. 19,3 mm lang. 
Each hard capsule is approximately 19.3 mm in length.
Kvinder i den fertile alder skal anvende sikker kontraception under behandling med zonisamid og i en måned efter seponering. 
Women of childbearing potential must use effective contraception during treatment with zonisamide, and for one month after discontinuation.
Abnorm urinsammensætning 
Urine abnormality
1 hård kapsel er ca. 14,4 mm lang. 
Each hard capsule is approximately 14.4 mm in length.
6 - 8 mg/kg/dag (én gang dagligt) 
6 to 8 mg/kg/day (once a day)
Infektioner og parasitære sygdomme 
Infections and infestation
• Sammen med andre antiepileptika til behandling af partielle anfald hos voksne, unge og børn på 
• with other antiepileptic medicines to treat seizures in adults, adolescents, and children aged 6 years and above.
Der bør gives medicinsk specialistrådgivning til kvinder i den fertile alder, der behandles med zonisamid. 
Specialist advice should be given to women treated with zonisamide who are of childbearing potential.
Alle partielle 
Simple partial
Det skal De vide, før De begynder at tage Zonisamide Mylan 
What you need to know before you take Zonisamide Mylan
Brug af anden medicin sammen med Zonisamide Mylan Fortæl det altid til lægen eller apotekspersonalet, hvis De bruger anden medicin eller har gjort det for nylig. 
Other medicines and Zonisamide Mylan Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Enkeltdosisblisterpakninger: 14 × 14 hårde kapsler 
Unit Dose Blisters: 14 x 1 hard capsules
Øges med 2-ugers intervaller i trin af 1 mg/kg 
Increase at twoweekly intervals in increments of 1 mg/kg
Enkeltdosisblisterpakninger: 56 × 1 hårde kapsler 
Unit Dose Blisters: 56 x 1 hard capsules
Passende evaluering og monitorering af serum-hydrogencarbonat skal udføres hos denne population (se hele advarslen i pkt. 
Appropriate evaluation and monitoring of serum bicarbonate levels should be carried out in this population (see section 4.4 - Metabolic acidosis for full warning; see section 4.8 for incidence of low bicarbonate).
Kvinder i den fertile alder skal anvende sikker kontraception under behandling med zonisamid og i en måned efter seponering (se pkt. 
Women of childbearing potential must use effective contraception during treatment with zonisamide and for one month after discontinuation (see section 4.6).
Urinvejsinfektioner Pneumoni 
Urinary tract infection Pneumonia
Kosttilskud eller øget fødeindtagelse skal overvejes, hvis patienten ikke tager på i vægt i henhold til vækstkurverne. 
A dietary supplement or increased food intake should be considered if the patient is failing to gain weight in accordance with growth charts, otherwise zonisamide should be discontinued.
Agranulocytose Aplastisk anæmi Leucocytose Leukopeni Lymphadenopathi Pancytopeni Trombocytopeni 
Agranulocytosis Aplastic anaemia Leucocytosis Leucopoenia Lymphadenopathy Pancytopenia, Thrombocytopenia
Forhøjet kreatininkinase i blodet 
Blood creatinine increased
> 4 anfald i løbet af 3-månedersbaselineperioden 
PP-population* ITT-population < 4 seizures during 3 month baseline period > 4 seizures during 3 month baseline period
Langtidsvirkningen af vægttab på vækst og udvikling hos børn og unge kendes ikke. 
The long term effect of weight loss in the paediatric population on growth and development is unknown.
Når zonisamid seponeres, bør det ske gradvist (se pkt. 
When zonisamide treatment is to be discontinued, it should be withdrawn gradually (see section 4.4).
Zonisamid må ikke bruges hos pædiatriske patienter samtidig med andre kulsyreanhydrasehæmmere såsom topiramat og acetazolamid (se pkt. 
Zonisamide should not be used as co-medication in paediatric patients with other carbonic anhydrase inhibitors such as topiramate and acetazolamide (see section 4.5).
Uforklarligt udslæt 
Unexplained rash
Øget kreatinin i blodet Øget carbamid i blodet Abnorme leverfunktionsprøver 
Blood urea increased Liver function tests abnormal
Bivirkninger forbundet med zonisamid, som blev set ved supplerende behandling i kliniske studier og overvågning efter markedsføring 
Adverse reactions associated with zonisamide obtained from adjunctive use clinical studies and post-marketing surveillance System Organ
Overfølsomhed over for det aktive stof eller over for et eller flere af hjælpestofferne anført i pkt. 
Hypersensitivity to the active substance, to any of the excipients listed in section 6.1 or to sulfonamides.
Nyresten er forekommet hos pædiatriske patienter (se den fuldstændige advarsel i pkt. 
Kidney stones have occurred in paediatric patients (see section 4.4 Kidney stones for full warning).
Uge 2-8 Patienter, der vejer 20 - 55 kg a 
Patients of weight 20 to 55 kga
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger til Lægemiddelstyrelsen: 
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
- med CYP3A4induktorer (se pkt. 
Adjunctive therapy - with CYP3A4inducing agents (see section 4.5)
Bivirkninger i et randomiseret, kontrolleret studie med monoterapi, der sammenlignede zonisamid med carbamazepin-depotformulering 
Adverse reactions in a randomised, controlled monotherapy trial comparing zonisamide with carbamazepine prolonged release System Organ Class (MedDRA terminology†)
Nedsæt risikoen for hedeslag ved at drikke rigeligt med vand og holde Dem i ro. 
Reduce the risk of kidney stones by drinking sufficient water - live in a place or are on holiday in a place where the weather is warm.
50 mg/dag (fordelt på 2 doser) 
50 mg/day (in two divided doses)
(langvarige eller gentagne krampeanfald). 
incontinence), status epilepticus (prolonged or repeated seizures)
• Hvis Deres læge råder Dem til at ophøre med at tage Zonisamide Mylan, vil Deres dosis gradvis blive reduceret for at mindske risikoen for flere anfald. 
Do not reduce your dose or stop your medicine unless your doctor tells you to. - If your doctor advises you to stop taking Zonisamide Mylan your dose will be reduced gradually to lower the risk of more seizures.
Svimmelhed Hukommelsesbesvær Døsighed 
Ataxia Dizziness Memory impairment Somnolence
Hos pædiatriske patienter (på 6 år og derover) er der vist virkning af zonisamid i et dobbeltblindt, placebokontrolleret studie, der omfattede 207 personer og havde en behandlingsvarighed på op til 24 uger. 
Adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adolescent and paediatric patients (aged 6 years and above) In paediatric patients (aged 6 years and above), efficacy has been demonstrated with zonisamide in a double-blind, placebo-controlled study, which included 207 subjects and had a treatment duration of up to 24 weeks.
Zonisamide Mylan tilhører en gruppe lægemidler (sulfonamider), der kan forårsage alvorlige allergiske reaktioner, alvorligt hududslæt og blodsygdomme, som i meget sjældne tilfælde kan være fatale. 
Zonisamide Mylan belongs to a group of medicines (sulfonamides) that can cause severe allergic reactions, severe skin rashes, and blood disorders, which very rarely can be fatal.
In-vitro studier viser, at dette ikke påvirkes af tilstedeværelsen af forskellige antiepileptika (dvs. phenytoin, phenobarbital, carbamazepin og natriumvalproat). 
Zonisamide is 40 - 50 % bound to human plasma proteins, with in vitro studies showing that this is unaffected by the presence of various antiepileptic medicinal products (i.e., phenytoin, phenobarbitone, carbamazepine, and sodium valproate).
Prægeblæk Shellac 
Printing ink Shellac
Zonisamid skal anvendes med forsigtighed hos voksne patienter, der samtidigt behandles med kulsyreanhydrasehæmmere som f.eks. topiramat eller acetazolamid, da der foreligger utilstrækkelige data til at udelukke en farmakodynamisk interaktion (se også pkt. 
Zonisamide should be used with caution in adult patients being treated concomitantly with carbonic anhydrase inhibitors such as topiramate or acetazolamide, as there are insufficient data to rule out a pharmacodynamic interaction (see also section 4.4 Paediatric Population and section 4.5).
Alvorlige immunbaserede bivirkninger, som har forbindelse med lægemidler indeholdende en sulfonamidgruppe, omfatter udslæt, allergisk reaktion og alvorlige hæmatologiske sygdomme, inklusive aplastisk anæmi, der i meget sjældne tilfælde kan være fatalt. 
Serious immune based adverse reactions that are associated with medicinal products containing a sulfonamide group include rash, allergic reaction and major haematological disturbances, including aplastic anaemia, which very rarely can be fatal.
Et øget tryk i øjet kan, uanset sygdomsårsag, have alvorlige følgevirkninger, hvis det ikke behandles, herunder permanent synstab. 
Elevated intraocular pressure of any aetiology, if left untreated, can lead to serious sequelae including permanent vision loss.
• De er ældre, fordi det kan være nødvendigt at justere Deres dosis af Zonisamide Mylan, og De kan have en større risiko for at udvikle en allergisk reaktion, alvorligt hududslæt, hævede fødder og ben samt kløe, når De tager Zonisamide Mylan (se pkt. 
If you are younger than 6 years old, Zonisamide Mylan is not recommended for you - are elderly, as your dose of Zonisamide Mylan may need adjusting, and you may be more likely to develop an allergic reaction, severe skin rash, swelling of the feet and legs, and itchiness when taking Zonisamide Mylan (see section 4 Possible Side Effects) - suffer from liver problems, as your dose of Zonisamide Mylan may need adjusting - have eye problems such as glaucoma - suffer from kidney problems as your dose of Zonisamide Mylan may need adjusting - have previously suffered from kidney stones, as you may be at increased risk of developing more kidney stones.
100 mg /dag (fordelt på 2 doser) 
100 mg/day (in two divided doses)
1 mg/kg/dag (én gang dagligt) 
1 mg/kg/day (once a day)
Zonisamide Mylan tilhører en gruppe lægemidler (sulfonamider), der kan forårsage alvorlige allergiske reaktioner, alvorligt hududslæt og blodsygdomme, som i meget sjældne tilfælde kan være dødelige (se pkt. 
Zonisamide Mylan belongs to a group of medicines (sulfonamides) which can cause severe allergic reactions, severe skin rashes, and blood disorders, which very rarely can be fatal (see section 4.
Blisterpakning 
BLISTER PACK
Psykiske forstyrrelser 
Psychiatric Disorders
Hos rotter sås der et fald i antallet af corpora lutea og implantationssteder ved eksponeringsniveauer, der svarer til den maksimale terapeutiske dosis hos mennesker. 
In rats, decreased numbers of corpora lutea and implantation sites were observed at exposure levels equivalent to the maximum therapeutic dose in humans; irregular oestrus cycles and a decreased number of live foetuses were observed at exposure levels three times higher.
Influenzalignende sygdom 
Fatigue Influenza-like illness
Perforeret PVC/PVDC-aluminiumsfolie-enkeltdosisblisterpakning i æsker af karton, der indeholder 14 × 1 kapsler. 
PVC-PVdC/Aluminium foil perforated unit dose blisters in cardboard cartons containing 14 x 1 capsules.
Nedsat hydrogencarbonat 
Decreased bicarbonate
300 mg dagligt (én gang dagligt). 
300 mg per day (once a day).
Zonisamid må ikke bruges til pædiatriske patienter sammen med andre lægemidler, som gør patienterne modtagelige for varmerelaterede sygdomme. 
Zonisamide should not be used as co-medication in paediatric patients with other medicinal products that predispose patients to heat related disorders; these include carbonic anhydrase inhibitors and medicinal products with anticholinergic activity.
Sort jernoxid (E172) 
Black iron oxide (E172) Potassium hydroxide
Alvorlige immunbaserede bivirkninger, som har forbindelse med lægemidler indeholdende en sulfonamidgruppe, omfatter udslæt, allergisk reaktion og alvorlige hæmatologiske sygdomme inklusive aplastisk anæmi, der i meget sjældne tilfælde kan være fatalt (se pkt. 
Serious immune based adverse reactions that are associated with medicinal products containing a sulfonamide group include rash, allergic reaction and major haematological disturbances including aplastic anaemia, which very rarely can be fatal (see section 4.4).
Zonisamide Mylan 25 mg hårde kapsler har en lys overdel og en lys underdel, er markeret med ”Z 25” i sort skrift og fyldt med lyst/næsten hvidt pulver. 
Zonisamide Mylan 25 mg hard capsules have a white body and a white cap, marked ‘Z 25' in black and contain a white/almost white powder.
• De er undervægtig eller har haft et stort vægttab, fordi Zonisamide Mylan kan betyde, at De taber Dem yderligere. 
Reduce the risk of overheating by drinking sufficient water and keeping cool - are underweight, or have lost a lot of weight as Zonisamide Mylan can cause you to lose more weight.
PVC/PVDC-aluminiumsfolie-enkeltdosisblisterpakning i æsker af karton, der indeholder 14, 25 og 56 kapsler. 
PVC-PVdC/Aluminium foil blisters in cardboard cartons containing 14, 28 and 56 capsules.
Zonisamide Mylan 100 mg hårde kapsler har en lys overdel og en lys underdel, er markeret med ”Z 100” i sort skrift og fyldt med lyst/næsten hvidt pulver. 
Zonisamide Mylan 100 mg hard capsules have a white body and white cap, marked ‘Z 100' in black and contain a white/almost white powder.
• Zonisamide Mylan er beregnet til at blive taget som langtidsbehandling. 
If you stop taking Zonisamide Mylan - Zonisamide Mylan is meant to be taken as a long-term medicine.
Zonisamide Mylan 50 mg hårde kapsler har en lys overdel og en lys underdel, er markeret med ”Z 50” i rød skrift og fyldt med lyst/næsten hvidt pulver. 
Zonisamide Mylan 50 mg hard capsules have a white body and white cap, marked ‘Z 50' in red and contain a white/almost white powder.
Uge 1+2 
Week 1 + 2 Weeks ≥ 3
Perforeret PVC/PVDC-aluminiumsfolie-enkeltdosisblisterpakning i æsker af karton, der indeholder 56 × 1 kapsler. 
PVC-PVdC/Aluminium foil perforated unit dose blisters in cardboard cartons containing 56 x 1 capsules.
J. Uriach y Compania S.A. Av. Cami Reial 51-57 
Av Cami Reial 51-57
Abdominalsmerter Obstipation Diaré 
Abdominal pain Constipation Diarrhoea Dyspepsia Nausea